MAPT and Alzheimer disease: Studies have already shown that raising cAMP levels reduced the aggregation of both mutant tau in a mouse model of tauopathy (associated with AD) (Myeku et al., 2016), and the aggregation of mutant huntingtin in an HD mouse model (as discussed in section 2.3.3) (Lin et al., 2013).